GB0115393D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0115393D0
GB0115393D0 GBGB0115393.1A GB0115393A GB0115393D0 GB 0115393 D0 GB0115393 D0 GB 0115393D0 GB 0115393 A GB0115393 A GB 0115393A GB 0115393 D0 GB0115393 D0 GB 0115393D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0115393.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Priority to GBGB0115393.1A priority Critical patent/GB0115393D0/en
Publication of GB0115393D0 publication Critical patent/GB0115393D0/en
Priority to HR20031049A priority patent/HRP20031049A2/en
Priority to EP02740895A priority patent/EP1404676A1/en
Priority to YU99203A priority patent/RS51698B/en
Priority to OA1200300335A priority patent/OA12632A/en
Priority to CA002451932A priority patent/CA2451932C/en
Priority to IL15950602A priority patent/IL159506A0/en
Priority to CNB028119320A priority patent/CN1294135C/en
Priority to PL02374096A priority patent/PL374096A1/en
Priority to AU2002314325A priority patent/AU2002314325B8/en
Priority to CZ20033443A priority patent/CZ20033443A3/en
Priority to EEP200400003A priority patent/EE05432B1/en
Priority to APAP/P/2003/002929A priority patent/AP2003002929A0/en
Priority to EA200400073A priority patent/EA007415B1/en
Priority to BR0210652-3A priority patent/BR0210652A/en
Priority to MXPA03011998A priority patent/MXPA03011998A/en
Priority to KR1020037016809A priority patent/KR100875380B1/en
Priority to TNPCT/GB2002/002835A priority patent/TNSN03144A1/en
Priority to NZ529766A priority patent/NZ529766A/en
Priority to TR2003/02242T priority patent/TR200302242T2/en
Priority to HK05100184.1A priority patent/HK1068134B/en
Priority to JP2003507098A priority patent/JP4344607B2/en
Priority to UA2004010502A priority patent/UA76760C2/en
Priority to SK1588-2003A priority patent/SK15882003A3/en
Priority to HU0400300A priority patent/HUP0400300A3/en
Priority to MEP-193/08A priority patent/MEP19308A/en
Priority to PCT/GB2002/002835 priority patent/WO2003000695A1/en
Priority to CR7193A priority patent/CR7193A/en
Priority to BG108453A priority patent/BG108453A/en
Priority to MA27444A priority patent/MA27129A1/en
Priority to NO20035728A priority patent/NO20035728L/en
Priority to IL159506A priority patent/IL159506A/en
Priority to CO03111600A priority patent/CO5540313A2/en
Priority to US10/744,478 priority patent/US7259154B2/en
Priority to EC2003004922A priority patent/ECSP034922A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0115393.1A 2001-06-23 2001-06-23 Chemical compounds Ceased GB0115393D0 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
PCT/GB2002/002835 WO2003000695A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
KR1020037016809A KR100875380B1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidine as a Protein Kinase Inhibitor
TNPCT/GB2002/002835A TNSN03144A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
YU99203A RS51698B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as Protein Kinase Inhibitors
OA1200300335A OA12632A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors.
CA002451932A CA2451932C (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
IL15950602A IL159506A0 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
CNB028119320A CN1294135C (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
PL02374096A PL374096A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
AU2002314325A AU2002314325B8 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
CZ20033443A CZ20033443A3 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
EEP200400003A EE05432B1 (en) 2001-06-23 2002-06-21 P rrolop rimidines as protein kinase inhibitors
APAP/P/2003/002929A AP2003002929A0 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
EA200400073A EA007415B1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
BR0210652-3A BR0210652A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
MXPA03011998A MXPA03011998A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors.
HR20031049A HRP20031049A2 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
NZ529766A NZ529766A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
EP02740895A EP1404676A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
TR2003/02242T TR200302242T2 (en) 2001-06-23 2002-06-21 Pyrolopyrimidines as protein kinase inhibitors
HK05100184.1A HK1068134B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
JP2003507098A JP4344607B2 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
UA2004010502A UA76760C2 (en) 2001-06-23 2002-06-21 Pyrrole pyrimidines as protein kinase inhibitors
SK1588-2003A SK15882003A3 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
HU0400300A HUP0400300A3 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
MEP-193/08A MEP19308A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
CR7193A CR7193A (en) 2001-06-23 2003-12-10 PIRROLOPIRIMIDINAS AS INHIBITORS OF THE KINASA PROTENINE
BG108453A BG108453A (en) 2001-06-23 2003-12-15 Pyrrolopyrimidines as protein kinase inhibitors
MA27444A MA27129A1 (en) 2001-06-23 2003-12-16 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS.
NO20035728A NO20035728L (en) 2001-06-23 2003-12-19 Pyrrolopyrimidines as protein kinase inhibitors
IL159506A IL159506A (en) 2001-06-23 2003-12-22 Pyrrolopyrimidines as protein kinase inhibitors
CO03111600A CO5540313A2 (en) 2001-06-23 2003-12-22 PIRROLOPIRIMIDINAS AS INHIBITORS OF PROTEIN QUINASA
US10/744,478 US7259154B2 (en) 2001-06-23 2003-12-23 Pyrrolopyrimidines
EC2003004922A ECSP034922A (en) 2001-06-23 2003-12-23 PIRROLOPIRIMIDINES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0115393D0 true GB0115393D0 (en) 2001-08-15

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0115393.1A Ceased GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
JP2006514989A (en) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ Method for treating and preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP1687309A1 (en) * 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
BRPI0416909A (en) * 2003-11-25 2007-01-16 Pfizer Prod Inc atherosclerosis treatment method
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
HUE025173T2 (en) 2005-12-13 2016-01-28 Incyte Corp Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
BRPI0719883A2 (en) 2006-10-09 2015-05-05 Takeda Pharmaceutical Kinase Inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
MX2010007523A (en) 2008-01-11 2010-08-18 Natco Pharma Ltd Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents.
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
LT2432472T (en) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3- [4- (7H-Pyrrolo [2,3-D] pyrimidine-4-IL) -1H-pyrazol-1-yl] octane or heptane nitrite as JAK INHIBITORS
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
SG10201407976UA (en) 2009-12-01 2015-01-29 Abbvie Inc Novel tricyclic compounds
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
TWI499421B (en) 2010-05-21 2015-09-11 Incyte Corp Topical formulation for a jak inhibitor
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
CN102093364B (en) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
ES2560611T3 (en) 2011-06-20 2016-02-22 Incyte Holdings Corporation Phenyl azetidinyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
JP6182593B2 (en) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド Substituted heterobicyclic compounds, compositions and medicaments and uses thereof
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
SI2877467T1 (en) 2012-07-26 2017-02-28 Glaxo Group Limited 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
JP6318156B2 (en) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for modulating kinases and indicators thereof
SG10202111768XA (en) 2012-11-15 2021-11-29 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
PE20200298A1 (en) 2013-03-06 2020-02-06 Incyte Holdings Corp PROCESSES AND INTERMEDIATES TO MAKE A JAK INHIBITOR
JP2016512559A (en) 2013-03-13 2016-04-28 アッヴィ・インコーポレイテッド CDK9 kinase inhibitor
BR112015021549A2 (en) 2013-03-13 2017-07-18 Abbvie Inc pyridine kinase cdk9 inhibitors
MX2015012153A (en) 2013-03-14 2015-12-01 Abbvie Inc Pyrrolopyrimindine cdk9 kinase inhibitors.
TW201444836A (en) 2013-03-14 2014-12-01 Abbvie Inc Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
BR112015023187A2 (en) 2013-03-14 2017-07-18 Abbvie Inc pyrrolo [2,3 - b] pyridine cdk9 kinase inhibitors
CN114010611B (en) 2013-08-07 2023-11-28 因赛特控股公司 Sustained release dosage forms of JAK1 inhibitors
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
TWI851536B (en) 2017-03-09 2024-08-11 美商艾伯維有限公司 Methods of treating crohn’s disease and ulcerative colitis
TW201924683A (en) 2017-12-08 2019-07-01 美商英塞特公司 Low dose combination therapy for treatment of myeloproliferative neoplasms
RS63312B1 (en) 2018-01-30 2022-07-29 Incyte Corp PREPARATION PROCESSES (1-(3-FLUORO-2-(TRIFLUOROMETHYL)ISONICOTYNYL)PIPERIDIN-4-ONE)
MX2020010322A (en) 2018-03-30 2022-11-30 Incyte Corp TREATMENT OF HYDRADENITIS SUPPURATIVA THROUGH THE USE OF INHIBITORS OF ACTIVITY OF JANUS KINASE (JAK).
IL282021B2 (en) 2018-10-05 2025-04-01 Annapurna Bio Inc Compounds and compositions for treating conditions associated with apj receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE217873T1 (en) * 1996-01-23 2002-06-15 Novartis Erfind Verwalt Gmbh PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
IL129825A0 (en) * 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
HUP0200355A3 (en) * 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
DE60037345T2 (en) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton -Pyrrolo (2,3-d) pyrimidin-compounds

Also Published As

Publication number Publication date
EE200400003A (en) 2004-02-16
CA2451932C (en) 2009-12-29
HUP0400300A2 (en) 2007-08-28
EA007415B1 (en) 2006-10-27
NZ529766A (en) 2008-11-28
ECSP034922A (en) 2004-04-28
EP1404676A1 (en) 2004-04-07
CN1294135C (en) 2007-01-10
JP4344607B2 (en) 2009-10-14
WO2003000695A1 (en) 2003-01-03
TR200302242T2 (en) 2004-12-21
TNSN03144A1 (en) 2005-12-23
RS51698B (en) 2011-10-31
JP2005508300A (en) 2005-03-31
BR0210652A (en) 2004-08-10
MEP19308A (en) 2010-06-10
PL374096A1 (en) 2005-09-19
UA76760C2 (en) 2006-09-15
WO2003000695A8 (en) 2004-03-11
SK15882003A3 (en) 2004-07-07
OA12632A (en) 2006-06-14
CN1518552A (en) 2004-08-04
AU2002314325B8 (en) 2009-01-29
HUP0400300A3 (en) 2010-12-28
EA200400073A1 (en) 2004-08-26
CZ20033443A3 (en) 2004-03-17
RS99203A (en) 2006-12-15
CA2451932A1 (en) 2003-01-03
AU2002314325B2 (en) 2009-01-08
EE05432B1 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
GB0115109D0 (en) Chemical compounds
GB0103926D0 (en) Chemical compounds
GB0103630D0 (en) Chemical compounds
GB0115393D0 (en) Chemical compounds
GB0107228D0 (en) Chemical compounds
AU2002366440A8 (en) Chemical compounds
GB0114005D0 (en) Chemical compounds
GB0108046D0 (en) Chemical compounds
GB0108793D0 (en) Chemical compounds
GB0108764D0 (en) Chemical compounds
GB0113231D0 (en) Chemical compounds
GB0106446D0 (en) Chemical compounds
GB0110797D0 (en) Chemical compounds
GB0101226D0 (en) Chemical compounds
GB0108594D0 (en) Chemical compounds
GB0104418D0 (en) Chemical compounds
GB0103628D0 (en) Chemical compounds
GB0106877D0 (en) Chemical compounds
GB0106871D0 (en) Chemical compounds
GB0108593D0 (en) Chemical compounds
GB0105077D0 (en) Chemical Compounds
GB0108654D0 (en) Chemical compounds
GB0115544D0 (en) Chemical compounds
GB0103990D0 (en) Chemical compounds
GB0109248D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)